Highlights From INNOVATE 2025
The I.N.N.O.V.A.T.E (International Neoadjuvant Immunotherapy Across Cancers) meeting, held July 11–12, 2025, at the Royal Continental Hotel in Naples, Italy, convened leading international experts to advance neoadjuvant immunotherapy as a transformative approach in cancer treatment and drug development.
The event focused on key areas such as pathology harmonization, surrogate endpoints, biomarker discovery, and cancer-specific strategies, while fostering active collaboration and interactive discussion. Through a series of keynote presentations and panel sessions, I.N.N.O.V.A.T.E highlighted the latest translational research and personalized approaches that are reshaping the future of oncology.
3P Solution shared Highlights From INNOVATE 2025 on LinkedIn:
“An inspiring start to our INNOVATE 2025 global meeting in Naples, where leaders in clinical and translational research came together to explore the transformative potential of neoadjuvant immunotherapy.
The first day discussions focused on:
- Neoadjuvant therapy as a practice-changing platform with significant promise for drug development.
- Pathology harmonization, emphasizing the need for consistent surrogate endpoints to better evaluate treatment efficacy.
- Personalized treatment approaches, using the neoadjuvant setting to tailor therapies to individual patient profiles.
The energy, collaboration, and forward-thinking ideas shared today set the tone for an exciting journey ahead. Looking forward to Day 2!
Scientific Board: Paolo A. Ascierto, Christian Blank, Liz Burton”
“INNOVATE 2025 Day 2 Highlights – Diving Deeper into Cancer-Specific Insights
The second day sessions focused on:
Cancer-specific updates in neoadjuvant immunotherapy:
- Lung
- Colorectal (CRC)
- Breast
- Gastroesophageal
- Melanoma and Non-melanoma skin cancers
- Head and neck
Translational insights:
Cross-cutting discussions on biomarkers and their role in guiding treatment across cancer types.
A heartfelt thank you to all the outstanding speakers for the high-level presentations and invaluable scientific contributions shared over the past two days.
The discussions around neoadjuvant immunotherapy, translational research, and personalized treatment strategies have truly set the stage for future progress.
We look forward to welcoming you again next year for another inspiring edition!
Scientific Board: Paolo A. Ascierto, Christian Blank, Liz Burton”
More posts featuring 3P Solution.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023